Total medical devices venture financing deals in Q4 2018 worth $1.84bn were announced globally, according to GlobalData’s deals database.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
The value marked a decrease of 22% over the previous quarter and a drop of 20.7% when compared with the last four-quarter average, which stood at $2.37bn.
Comparing deals value in different regions of the globe, North America held the top position, with total announced deals in the period worth $1.47bn. At the country level, the United States topped the list in terms of deal value at $1.44bn.
In terms of volumes, North America emerged as the top region for medical devices venture financing deals globally, followed by Europe and then Asia-Pacific.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe top country in terms of venture financing deals activity in Q4 2018 was the United States with 127 deals, followed by the United Kingdom with 11 and China with eight.
In 2018, as of the end of Q4, medical devices venture financing deals worth $8.9bn were announced globally, marking a decrease of 9% year on year.
Medical devices venture financing deals in Q4 2018: Top deals
The top five medical devices venture financing deals accounted for 33.4% of the overall value during Q4 2018.
The combined value of the top five medical devices venture financing deals stood at $614.5m, against the overall value of $1.84bn recorded for the quarter.
The top announced medical devices venture financing deal tracked by GlobalData in Q4 2018 was Ireland Strategic Investment Fund, Sequoia Capital Operations, Temasek International and Yunfeng Capital’s $200m venture financing of WuXi NextCODE Genomics.
In second place was TPG Sixth Street Partners’ venture financing of Caris Life Sciences for $150m and in third place was 8VC, Founders Fund and Menlo Ventures’ $110m venture financing of Synthego.
Aisling Capital, ARCH Healthcare Fund, Cochlear, CRG PARTNERS, Exor Seeds, Far East Ventures, GDN Holdings, KCK, LSV Capital Management, New Enterprise Associates , Relativity Healthcare Fund, Richard King Mellon Foundation, SightLine Partners, Vertex Healthcare and Windham Venture Partners’ $87m venture financing of EarLens and 5AM Venture Management, KKR & Co, Norwest Venture Partners XII, venBio Partners and Vivo Capital’s venture financing of Impel NeuroPharma for $67.5m held fourth and fifth positions, respectively.
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.
